> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Shionogi Expanded Use for Fetroja
- URL: https://www.fdaweb.com/shionogi-expanded-use-for-fetroja/
- Published: 2020-09-28T12:00:00.000Z
- Updated: 2026-09-14T16:30:26.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147748

FDA has approved a Shionogi & Co. supplemental NDA for Fetroja (cefiderocol) for treating patients 18 years of age or older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by the following susceptible Gram-negative microorganisms: *Acinetobacter baumannii* complex, *Escherichia coli*, *Enterobacter cloacae* complex, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and *Serratia marcescens.* The expanded indication is based on the results from the Phase 3 APEKS-NP study, which showed Fetroja met the primary endpoint of non-inferiority compared to high-dose extended-infusion meropenem in all-cause mortality 14 days after initiation of the study drug in the target population, the company says. Fetroja is currently approved for patients 18 years of age or older for treating complicated urinary tract infections, including pyelonephritis, caused by Gram-negative pathogens.